Vertex Pharmaceuticals
VRTX
411 hedge funds and large institutions have $21.7B invested in Vertex Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 58 funds opening new positions, 136 increasing their positions, 162 reducing their positions, and 39 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
49% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 39
37% more capital invested
Capital invested by funds: $15.8B → $21.7B (+$5.85B)
26% more call options, than puts
Call options by funds: $910M | Put options by funds: $724M
4% more funds holding
Funds holding: 395 → 411 (+16)
16% less repeat investments, than reductions
Existing positions increased: 136 | Existing positions reduced: 162
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$450M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$143M |
| 3 |
JP Morgan Chase
New York
|
+$142M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$109M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$91.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$88.8M |
| 2 |
O
OppenheimerFunds
New York
|
-$83M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$74.2M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$73.4M |
| 5 |
D.E. Shaw & Co
New York
|
-$68.3M |
VRTX Hedge Fund Activity: Q2 2014 in Review
411 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2014, worth a combined $21.7B — up 37% from $15.8B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new VRTX positions and 39 closed out — a net gain of 19 holders — while 136 added to existing stakes and 162 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $450M. The largest seller was AllianceBernstein, cutting an estimated $88.8M.
- 411 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2014, up from 395 in Q1 2014.
- Funds reported $21.7B of Vertex Pharmaceuticals stock for Q2 2014, up 37% quarter-over-quarter.
- 58 funds opened new Vertex Pharmaceuticals positions in Q2 2014 and 39 closed out, a net change of +19 holders.
- The largest Vertex Pharmaceuticals buyer in Q2 2014 was Fidelity Investments, an estimated $450M added.
- The largest Vertex Pharmaceuticals seller in Q2 2014 was AllianceBernstein, an estimated $88.8M sold.
Based on aggregated 13F filings for Q2 2014.